Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Dordaviprone + Panobinostat |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Dordaviprone | Modeyso | TIC-10|TIC10|ONC201 | Akt Inhibitor (Pan) 22 ERK Inhibitor (pan) 21 | Modeyso (dordaviprone) is a small molecule dopamine receptor D2 (DRD2) antagonist (PMID: 31702782) that induces TRAIL signaling (PMID: 23390247) and activates the mitochondrial protease, ClpP (PMID: 31021596), leading to anti-tumor activity (PMID: 31456142, PMID: 31702782). Modeyso (dordaviprone) is FDA-approved for use in adult and pediatric patients 1 year and older with diffuse midline glioma harboring an H3 K27M mutation who progressed on prior therapies (FDA.gov). |
| Panobinostat | Farydak | LBH589 | HDAC Inhibitor 45 | Farydak (panobinostat) is an HDAC inhibitor, which induces cell-cycle arrest and decreases growth of tumor cells (PMID: 18349321, PMID: 19671764, PMID: 27802904). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05009992 | Phase II | Dordaviprone + GDC-0084 Dordaviprone + Panobinostat | Combination Therapy for the Treatment of Diffuse Midline Gliomas | Recruiting | USA | NZL | NLD | ISR | CHE | AUS | 0 |